This defines the markets in which the licensee can exploit the technology. When important research results are published, numerous requests for the reagents described often result. It is both an ethical responsibility of scientists and an NIH guideline that those reagents are made available to other scientists. An invention that is relevant only to the research market normally will not be worth patenting. In vivo diagnostics require significantly more regulatory review than do in vitro products.
Therapeutics take many years for demonstration of safety and efficacy, preclinically and clinically.
Less than five percent of products that enter development ever reach the market, and licensees generally seek to structure arrangements that share the risk of failure with the University. Type of License A license is usually either exclusive or nonexclusive. An exclusive license grants all rights for a particular field and territory to a single licensee. The licensee is normally given rights to sublicense others to exploit the technology. The University will normally write specific development milestones into such a license agreement.